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ABSTRACT:
NSP 5a3a is a novel structural protein found to be over-expressed in certain cancer 
cell lines in-vitro such as Hela, Saos-2, and MCF-7 while barely detectable levels 
in normal body tissues except for Testis. This particular isoform has been known 
to interact with cyto- nuclear proteins B23, known to be involved in multi-faceted 
cellular processes such as cell division, apoptosis, ribosome biogenesis, and rRNA 
processing, as well as with hnRNP-L, known to be involved with RNA metabolism 
and rRNA processing. A previous preliminary investigation of NSP 5a3a as a potential 
target in Head and Neck Carcinoma revealed a novel p73 dependent mechanism 
through which NSP 5a3a induced apoptosis in Head and Neck cell lines when over-
expressed in-vitro. Our present investigation further elucidated a novel dual axis 
signaling point by which NSP 5a3a induces apoptosis in Head and Neck cell line 
HN30 through p73-DAXX and TRAF2-TRADD. Interestingly, this novel mechanism 
appears independent of canonical caspases involved in the intrinsic mitochondrial 
pathway as well as those in the death receptor pathway thru TRAF2 and TRADD. 
INTRODUCTION
Head and Neck squamous cell carcinomas 
(HNSSCs) being the fifth or sixth most common form 
of  cancer  worldwide  depending  on  sources  [8-9]  has 
shown an increasing incidence with greater than 40,000 
cases diagnosed each year in the United States and 
approximately 500,000 globally [10] though in the last 
forty years there has been no significant improvement in 
overall mortality and survival from this aggressive form 
of cancer [11-12]. Typically, the 5-year survival rates have 
been around 50% in the past twenty years, due to the lack 
of positive prognosis and reliable tumor markers for this 
pathological and biological diverse type of cancer hence 
its diverse clinical profiles and treatment [13]. Usually, 
general  treatment  involves  surgery  or  combination  of 
radiation  and  chemotherapy.  Most  patients  will  suffer 
from  recurrences,  whether  locally  or  regionally,  being 
from primary sites or becoming metastatic and spreading 
throughout the lymph nodes even still after surgery and 
or  in  combination  with  chemotherapy,  will  experience 
within two years and with significant decrease in overall 
survival by a half [14-16]. HNSSC can originate from 
various parts of the upper digestive/oral tract being and 
including larynx, oral and nasal cavities, pharynx, and 
esophagus  [17].  HNSSC’s  can  occur  from  common 
carcinogens  found  in  tobacco  products  as  well  as  in 
combination or not with of alcohol consumption [18-19] 
though there are cases of HNSSC where the cause is viral 
being from HPV (Human Papilloma virus) in about 30% 
of cases [20]. Thus, given the general poor prognosis and 
high risk of cancerous recurrences even from secondary 
primary tumor sites, there is push through development 
of  novel  biologic  therapies  including  gene  therapy  to 
promote better tumor growth control or regression with 
higher survival rates. Such strategies have included p53 
based adenoviral gene therapy [21] as well as Fas ligand 
adenoviral gene therapy [22].
Apoptosis also known as programmed cell death or 
cell suicide is a critical complex intrinsic cellular process 
involved in normal tissue homeostasis and development. 
This highly evolutionary conserved process occurs not 
only in normal cellular and tissue physiology but has been 
implicated in various pathological diseases such as cancer, 
autoimmune diseases, and dementia [23-29]. Typically, 
apoptosis is characterized by distinct morphological and Oncotarget 2011; 2:  1055 - 1074 1056 www.impactjournals.com/oncotarget
biochemical features which include shrinkage of the cell 
followed  by  cleavage  of  cytoskeletal  components  such 
as  actin  and  lamins,  nuclear  condensation  and  DNA 
fragmentation,  ending  with  membrane  blebbing  and 
apoptotic bodies in late stage apoptosis [30-32].
Apoptosis can be initiated either through extrinsic 
or intrinsic signaling pathways which involve the death 
receptor ligand complex and mitochondria, respectively. 
Activation  of  the  extrinsic  pathway  usually  involves 
the  tumor  necrosis  family  (TNF)  receptor  superfamily 
including  TNFR1,  TRAIL-R1,  TRAIL-R2,  or  CD95 
(APO-1-Fas)  involving  its  trimeric  membrane  receptor 
formation upon contact with its appropriate extracellular 
ligand  and  recruitment  of  adaptor  molecules  [33].  In 
the case of CD95 and TRAIL induced apoptosis, there 
is recruitment of FADD adaptor molecule and caspase 
8  which  becomes  activated  and  cleaves  downstream 
effector caspases such as caspase 3, 6, and 7 depending on 
the cell type or there is involvement of the mitochondria 
in a positive feedback loop thru cleavage of Bid [34-35]. 
While, in the case of TNF-R1 induced apoptosis, there is 
recruitment of adaptor molecules TRADD with FADD, 
or with RAIDD, which can lead to caspase 8 activation 
followed  by  subsequent  cleavage  and  activation  of 
downstream effector caspases such as caspase 3, 6, and 7 
or caspase 2 activation converging on the same activation 
of  effector  caspases  as  mentioned  before  [36-38].  The 
intrinsic  pathway  also  known  as  the  mitochondrial 
pathway, involves the release of apoptotic factors from 
the mitochondrial intermembrane space such as apoptosis 
inducing factor (AIF), cytochrome c, or Smac/DIABLO. 
The  release  of  cytochrome  into  the  cytoplasm  allows 
the  formation  of  an  apoptosome  complex  formed  by 
cytochrome c, Apaf-1, and caspase 9 which subsequently 
activates  caspase  3  [39-41].  Whereas  SMAC/DIABLO 
help  enhance  caspase  activation  by  inhibiting  anti-
apoptotic  factors  such  as  IAPs  (inhibitors  of  apoptosis 
proteins) while AIF causes changes in DNA condensation 
[42-44]. Both pathways can be interconnected at different 
points such as in the case of caspase 8, where it can initiate 
the mitochondrial pathway by by cleavage of BID, leading 
to BAX/BAK dependent cytochrome c release from the 
mitochondria  and  apoptosome  formation  resulting  in 
caspase 9 activation [44-45]. Then, subsequent caspase 
activation  of  caspases  3  and  7  can  occur  with  further 
activation of caspases of 2 and 6. Though, it has been noted 
that when particular caspases are impaired functionally 
or not expressed, other caspases along the cascade can 
continue the processing to downstream effectors [46].
TRAF2 (tumor necrosis factor receptor associated 
factor) is a member of a highly evolutionary conserved 
family of adaptor proteins (TRAFs) which have been found 
to participate in a multitude of biological processes such 
as: immunity, embryonic development, stress responses 
and  bone  metabolism  being  mediated  thru  TRAFs 
signaling  leading  to  cell  proliferation,  differentiation, 
and apoptosis [47]. The biological effects caused by the 
TRAF signaling, is possible through the activation of NF-
kB and AP-1 pathways which lead usually to cell survival 
and apoptosis, respectively [48-50] though there is also 
evidence of NF-kB and AP-1 pathways being involved 
in apoptosis and cell proliferation as well, respectively 
[51-52]. Upon TNFR1 stimulation, depending on cellular 
microenvironment and stimuli, TRAF2 can be recruited 
to form a complex with another adaptor protein known as 
TRADD which associates with the death domain regions 
of  the  trimerized TNFR1  through  its  own  intracellular 
death domains, also being able to recruit other signaling 
molecules such as FADD and RIP [53-54]. Depending on 
which signaling complex is released from TNFR1, there 
can be downstream activation of NF-kB through TRAF2/
RIP  complex  resulting  in  pro-survival  genes  or  even 
AP-1 activation by TRAF2 through upstream activation 
of ASK1/JNK leading to apoptosis. Should the levels of 
TRAF2 be deficient in the cytoplasm or absent along with 
limited accessibility of anti-apoptotic proteins c-IAP and 
FLICE, then the TRADD/FADD along with caspase 8 can 
initiate downstream caspase activation with subsequent 
apoptosis [54-57]. 
P73,  a  transcription  factor  belonging  to  the  p53 
family, is known to have shared and distinct functions 
with other p53 members, though all involved in regulating 
the  fate  of  cells  between  cell  growth  and  apoptosis 
during normal development, differentiation, and cellular 
stress  [58-60],  it  has  been  shown  to  be  specifically 
involved  in  biological  processes  such  as  neurogenesis, 
immunity  and  negative  regulation  of  p53  activity  [61-
63]. P73 in common with other p53 members can bind 
and transcriptionally differently activate p53 target genes 
which can be involved in apoptosis and cell cycle arrest. 
Depending on the particular p53 member that is expressed 
and which isoforms in that particular tissue or cells will 
determine the overall fate [64-65]. P73 can exist in multiple 
isoforms being either amino-terminal or carboxy-terminal 
splice variants of the full length Tap73 isoform in which 
the full length and carboxy-terminal truncated isoforms 
have been associated with pro-apoptotic functions along 
with cell growth arrest and tumor suppression while the 
truncated  amino  terminal  isoforms  ∆Np73  have  been 
associated with primarily anti-apoptotic functions as well 
as having negative regulatory activities on p53 and TAp73 
isoforms [65-67]. Different modes of action have been 
attributed to p73 in the induction of apoptosis, which have 
primarily been linked to either DNA damage or cytosolic 
stress. Once activated and depending on the stimuli, p73 
particularly  TAp73  can  induce  apoptosis  through  ER 
stress via the transactivation of Scotin, or can activate the 
mitochondrial intrinsic pathway through transactivation 
of PUMA with subsequent translocation and activation 
of BAX, as well as activate the death receptor pathway 
[68].  Interestingly,  in  regards  to  the  activation  of  the 
death  receptor  pathway,  p73  has  been  shown  to  have Oncotarget 2011; 2:  1055 - 1074 1057 www.impactjournals.com/oncotarget
transcriptional  activity  in  the  sensitization  of  cells  to 
apoptosis  through  a  Fas  mediated  caspase  dependent 
mechanism [69] as well as being involved in ASK1/JNK 
signaling  leading  to  apoptosis  [70-71],  by  which  this 
pathway has been linked to Fas signaling through DAXX 
which has been shown to interact with p73 [72].
NSP  5a3a  along  with  three  other  splice  variants 
isoforms:  NSP  5b3a,  5a3b,  and  5b3b  were  identified 
having slight homology to DNA repair Sbc proteins and 
SMC  (structural  maintenance  chromosome)  proteins 
while higher homology to Specc1 and Cytospin A renal 
carcinoma  antigen  was  observed  whose  functions  are 
functions are yet to characterized. These NSP isoforms 
having features of Spectrin like repeat proteins suggests 
they  may  be  novel  members  of  this  superfamily  of 
proteins which can be involved in a plethora of cellular 
activities  ranging  from  intracellular  structural  integrity 
in  the  cytoskeleton  and  matrix  in  both  the  cytoplasm 
and  nucleus  [73-74]  to  intracellular  trafficking  [75], 
maintenance  of  organelle  function,  integrity  [75],  and 
endocytosis [76], nuclear reassembly in Telophase [77], to 
being scaffolding proteins with other cytoskeletal proteins 
involved in signal transduction pathways [78].
The NSP 5a3a isoform was found to be expressed 
Figure 1: Morphological observation of HN30 cells 3 days post-transfection. NT: non-treated, OB: only buffer, EGFP: only 
pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.
Figure 2: Morphological observation of MCF-12a cells 3 days post-transfection. NT: non-treated, OB: only buffer, EGFP: 
only pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.Oncotarget 2011; 2:  1055 - 1074 1058 www.impactjournals.com/oncotarget
differently in-vitro, while moderate in some other showed 
higher levels of expression such as: HT-29, MCF-7, Hela, 
HN30, Saos-2, CEM, and H23 [1]. NSP 5a3a was shown 
to interact with B23, a multi-functional nucleolar in Hela 
cells both in cycling and in dividing cells. This suggested 
a likely involvement of NSP 5a4a during cell division 
with B23 and as well as other B23 functions pathways 
[2]. Subsequently, we showed and verified that NSP 5a3a, 
B23,  and  hnRNP-L  (heterogeneous  ribonuclearprotein) 
interacted  with  each  other  in  both  MCF-7  (breast 
adenocarcinoma)  and  MCF-12A  (normal  breast)  cell 
lines though in a both compartment and cell-type specific 
manner [4]. This novel interaction between NSP 5a3a with 
B23 and hnRNP-L raised the possibility of implicating 
NSP 5a3a in RNA metabolism and RNA processing both 
of which B23 and hnRNP-L have been confirmed to have 
important roles involving RNA processing and regulation 
[5-6].
Our  previous  study  had  demonstrated  that  over-
expression  of  NSP  5a3a  induced  significant  apoptosis 
in  head  and  neck  carcinoma  cell  lines  in  particular  in 
HN30 being p53 independent yet involving a novel p73 
dependent mechanism. Thus, we had proposed NSP 5a3a 
as a potential therapeutic target to be investigated further, 
since  it  could  have  potential  in  a  site-directed  manner 
to treat cancer types that behave through a similar p73 
dependent  mechanism  as  found  in  the  head  and  neck 
carcinoma cell lines we investigated previously [7]. We 
further elucidated this novel p73 mechanism thru NSP 
5a3a showing the involvement of TNF associated proteins 
TRAF2  and  TRADD  along  with  the  TGF-beta/FAS 
associated apoptotic protein DAXX.
RESULTS
Morphological and Immunofluorescence analysis 
of HN30 over-expressing NSP 5a3a
Asynchronous  HN30  cells  were  transfected  with 
pcDNA3.0 NSP 5a3a vector along with controls after which 
images of the cells were taken three days post-transfection 
and prepared for immune-staining to assess the effect of 
NSP 5a3a over-expression on protein distribution of NSP 
5a3a, p73, TRAF2, and TRADD. Images of HN30 cells 
three  days  post-transfection  revealed  that  treated  cells 
with NSP 5a3a seemed more stressed with appearance of 
floating cells and fewer attached cells to the plate surface 
indicative of possible apoptosis (Fig. 1). Controls were 
seemingly still confluent and well attached to plate surface 
(Fig. 1.). Immunostaining for NSP 5a3a in non-treated cells 
localized NSP 5a3a to mostly the nucleus while in cells 
over-expressing NSP 5a3a, there seemed to be a greater 
distribution into the cytoplasm along with a seemingly 
increase staining in the nucleus as well as the presence 
of possible protein aggregates containing NSP 5a3a with 
staining  near  and  in  likely  association  with  apoptotic 
bodies. The cells over-expressing NSP 5a3a showed signs 
of apoptosis such as horse-shoe appearance of the nucleus 
Figure 3: Immunostaining of HN30 and MCF-12a cells for NSP 5a3a 3 days post-transfection. MCF-12a NT (DAPI): non-
treated MCF-12a DAPI stained, MCF-12a NT (NSP 5a3a-FITC): non-treated MCF-12a FITC stained for NSP 5a3a, MCF-12a pNSP 5a3a 
(DAPI): MCF-12a transfected with pcDNA 3.0 NSP 5a3a DAPI stained, MCF-12a pNSP 5a3a (NSP 5a3a-FITC): MCF-12a transfected 
with pcDNA 3.0 NSP 5a3a FITC stained for NSP 5a3a, HN30 NT (DAPI): non-treated HN30 DAPI stained, HN30 NT (NSP 5a3a-FITC): 
non-treated HN30 FITC stained for NSP 5a3a, HN30 pNSP 5a3a (DAPI): HN30 transfected with pcDNA 3.0 NSP 5a3a DAPI stained, 
HN30 pNSP 5a3a (NSP 5a3a-FITC): HN30 transfected with pcDNA 3.0 NSP 5a3a FITC stained for NSP 5a3a. White arrows indicate 
apoptotic bodies.Oncotarget 2011; 2:  1055 - 1074 1059 www.impactjournals.com/oncotarget
and evidence of apoptotic bodies and blebs as indicated 
from the DAPI staining (Fig. 3). Immunostaining for p73 in 
non-treated cells localized p73 to mostly the nucleus with 
slight cytoplasmic staining while in cells over-expressing 
NSP 5a3a, there seemed to be a more diffuse distribution 
of p73 into the cytoplasm (Fig. 4). Immunostaining for 
TRAF2 in non-treated cells localized TRAF2 to both a 
diffuse localization in the cytoplasm and nucleus while 
in cells over-expressing NSP 5a3a, there seemed to be an 
increase of localization of TRAF2 into the cytoplasm as 
well as in association with protein bodies or aggregates 
as  well  as  staining  near  and  in  likely  association  with 
apoptotic  bodies  (Fig.  5).  Finally,  immunostaining  for 
TRADD in non-treated cells localized TRADD to mostly 
the nucleus while in cells over-expressing NSP 5a3a, there 
seemed to be an increase in the localization of TRADD 
in the cytoplasm, nucleus, and also in association with 
protein bodies or aggregates along with staining near and 
in likely association of apoptotic bodies (Fig. 6).
Morphological and immunofluorescence analysis 
of MCF-12a over-expressing NSP 5a3a
Asynchronous  MCF-12a  cells  were  transfected 
with  pcDNA3.0  NSP  5a3a  vector  along  with  controls 
after  which  images  of  the  cells  were  taken  three  days 
post-transfection  and  prepared  for  immune-staining  to 
assess the effect of NSP 5a3a over-expression on protein 
distribution  of  NSP  5a3a,  p73,  TRAF2,  and  TRADD. 
Images  of  MCF-12a  cells  three  days  post-transfection 
revealed that treated cells with NSP 5a3a seemed quite 
confluent and well attached to the plate surface comparable 
to the controls (Fig. 2). Immunostaining for NSP 5a3a in 
non-treated cells localized NSP 5a3a to mostly the nucleus 
while in cells over-expressing NSP 5a3a, there seemed to 
be a similar distribution to mostly nuclear and nuclear 
integrity of cells over-expressing NSP 5a3a showed no 
evident signs of cellular membrane stress as compared 
to the non-treated cells (Fig. 3). Immunostaining for p73 
in non-treated cells localized p73 to mostly the nucleus 
while in cells over-expressing NSP 5a3a, there seemed to 
be a more diffuse localization of p73 into the cytoplasm 
while still being quite nuclear (Fig. 4). Immunostaining 
for  TRAF2  in  non-treated  cells  localized  TRAF2  to 
both a diffuse localization in the cytoplasm and nucleus 
while in cells over-expressing NSP 5a3a, there seemed 
to  be  an  increase  of  localization  of  TRAF2  into  the 
nucleus while still appearing in the cytoplasm (Fig. 5). 
Finally, immunostaining for TRADD in non-treated cells 
localized TRADD to mostly the nucleus while in cells 
over-expressing NSP 5a3a, there seemed to be a more 
diffuse localization of TRADD into the cytoplasm while 
still being localized in the nucleus (Fig. 6).
Molecular analysis of NSP 5a3a over-expression 
in HN30
Western blot analysis of total lysates of HN30 cells 
from three days post-transfection along with controls were 
analyzed to better understand and explain the mechanism 
Figure 4: Immunostaining of HN30 and MCF-12a cells for p73 3 days post-transfection. MCF-12a NT (DAPI): non-treated 
MCF-12a DAPI stained, MCF-12a NT (p73-FITC): non-treated MCF-12a FITC stained for p73, MCF-12a pNSP 5a3a (DAPI): MCF-12a 
transfected with pcDNA 3.0 NSP 5a3a DAPI stained, MCF-12a pNSP 5a3a (p73-FITC): MCF-12a transfected with pcDNA 3.0 NSP 5a3a 
FITC stained for p73, HN30 NT (DAPI): non-treated HN30 DAPI stained, HN30 NT (p73-FITC): non-treated HN30 FITC stained for p73, 
HN30 pNSP 5a3a (DAPI): HN30 transfected with pcDNA 3.0 NSP 5a3a DAPI stained, HN30 pNSP 5a3a (p73-FITC): HN30 transfected 
with pcDNA 3.0 NSP 5a3a FITC stained for p73. White arrows indicate apoptotic bodies.Oncotarget 2011; 2:  1055 - 1074 1060 www.impactjournals.com/oncotarget
Figure 5: Immunostaining of HN30 and MCF-12a cells for TRAF2 3 days post-transfection. MCF-12a NT (DAPI): non-
treated MCF-12a DAPI stained, MCF-12a NT (TRAF2-FITC): non-treated MCF-12a FITC stained for TRAF2, MCF-12a pNSP 5a3a 
(DAPI): MCF-12a transfected with pcDNA 3.0 NSP 5a3a DAPI stained, MCF-12a pNSP 5a3a (TRAF2-FITC): MCF-12a transfected with 
pcDNA 3.0 NSP 5a3a FITC stained for Traf-2, HN30 NT (DAPI): non-treated HN30 DAPI stained, HN30 NT (TRAF2-FITC): non-treated 
HN30 FITC stained for TRAF2, HN30 pNSP 5a3a (DAPI): HN30 transfected with pcDNA 3.0 NSP 5a3a DAPI stained, HN30 pNSP 5a3a 
(TRAF2-FITC): HN30 transfected with pcDNA 3.0 NSP 5a3a FITC stained for TRAF2. White arrows indicate apoptotic bodies.
Figure 6: Immunostaining of HN30 and MCF-12a cells for TRADD 3 days post-transfection. MCF-12a NT (DAPI): non-
treated MCF-12a DAPI stained, MCF-12a NT (TRADD-FITC): non-treated MCF-12a FITC stained for TRADD, MCF-12a pNSP 5a3a 
(DAPI): MCF-12a transfected with pcDNA 3.0 NSP 5a3a DAPI stained, MCF-12a pNSP 5a3a (TRADD-FITC): MCF-12a transfected with 
pcDNA 3.0 NSP 5a3a FITC stained for Tradd, HN30 NT (DAPI): non-treated HN30 DAPI stained, HN30 NT (TRADD-FITC): non-treated 
HN30 FITC stained for TRADD, HN30 pNSP 5a3a (DAPI): HN30 transfected with pcDNA 3.0 NSP 5a3a DAPI stained, HN30 pNSP 5a3a 
(TRADD-FITC): HN30 transfected with pcDNA 3.0 NSP 5a3a FITC stained for TRADD. White arrows indicate apoptotic bodies.Oncotarget 2011; 2:  1055 - 1074 1061 www.impactjournals.com/oncotarget
that  NSP  5a3a  may  be  involved  to  induce  apoptosis 
as previously described in the HN30 cell line[28]. We 
considered and examined apoptotic proteins belonging to 
the caspase family that were not previously investigated 
in addition to proteins associated with the TNF signaling 
pathway such as TRAF-2 and TRADD. This was done 
so in light of the fact that NSP 5a3a over-expression was 
shown to affect the expression levels of p73 [7] while 
p73 has been suggested to be regulated by death receptor 
signaling pathways involving Daxx [72] but also given 
the fact that potential binding motifs had been previously 
found on NSP 5a3a for apoptotic proteins associated with 
TNF/death receptor signaling [7]. TRADD levels seemed 
apparently the same between treated and controls. TRAF2 
levels demonstrated a slight increase in a 190 kDa band 
in the transfected cells with a slight decrease in the 130 
and 112 kDa bands in the treated cells compared to the 
controls.  Though,  interestingly  there  was  a  moderate 
increase in the 55 kDa band compared to the controls while 
a 45 kDa band was comparable between transfected and 
controls. P73 levels demonstrated a significant decrease in 
the 140 kDa bands in transfected cells along with a slight 
decrease in a 55 kDa band and significant decrease in a 45 
kDa bands in treated cells compared to the controls. The 
Figure 7: Immunostaining controls of HN30 and MCF-12a cells for secondary anti-rabbit FITC and autofluorescence.
Figure 8: Western Blot analysis of total lysates from asynchronous HN30 cells 3 days post-transfection. NT: non-treated, 
OB: only buffer, EGFP: only pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.Oncotarget 2011; 2:  1055 - 1074 1062 www.impactjournals.com/oncotarget
72 kDa band remained comparable between treated and 
controls. B23 levels were seemingly unaffected between 
treated  and  controls.  DAXX  levels  were  not  detected 
in controls though a band approximately around 72-75 
kDa was detected in transfected HN30 cells showing a 
significant increase compared to controls as well as bands 
around 55 and 120 kDa were detected in transfected cells 
but not detected in the controls. Also interestingly, NSP 
5a3a levels showed the appearance of a lower band around 
around 55 to 60 kDa range in the transfected cells (Fig. 8). 
Figure 10: Western blot analysis of co-immunoprecipitations of asynchronous HN30 non-treated and HN30 cells 
transfected with pcDNA 3.0 NSP 5a3a and pcDNA 3.1/CT-GFP for 3 days. NT: non-treated HN30 cells, TRD: HN30 cells 
over-expressing NSP 5a3a. a. Immunoprecipitation of non-treated HN30 cells using rabbit anti-NSP 5a3a and western blot analysis using 
rabbit anti-DAXX., b. Immunoprecipitation of HN30 treated cells using rabbit anti-NSP 5a3a and western blot anaylsis using rabbit 
anti-DAXX., c. Immunoprecipitation of non-treated HN30 cells using rabbit anti-NSP 5a3a and western blot analysis using rabbit anti-
TRAF2., d. Immunoprecipitation of HN30 treated cells using rabbit anti-NSP 5a3a and western blot analysis using rabbit anti-TRAF2., 
e. Immunoprecipitation of non-treated HN30 cells using rabbit anti-TRAF2/DAXX and western blot analysis using rabbit anti-NSP 5a3a, 
and f. Immunoprecipitation of HN30 treated cells using rabbit anti-TRAF2/DAXX and western blot analysis using rabbit anti-NSP 5a3a.
Figure 9: Western Blot analysis of total lysates from asynchronous MCF-12a cells 3 days post-transfection. NT: non-
treated, OB: only buffer, EGFP: only pcDNA3.1/CT-GFP vector, NSP 5a3a/EGFP: pcDNA 3.1/CT-GFP and pcDNA 3.0 NSP 5a3a.Oncotarget 2011; 2:  1055 - 1074 1063 www.impactjournals.com/oncotarget
Cleaved caspase 7, 8, 9, and 1 were not detected in both 
transfected and controls (data not shown).
Molecular analysis of NSP 5a3a over-expression 
in MCF-12a
Western  blot  analysis  of  total  lysates  of  MCF-
12a  cells  from  three  days  post-transfection  along  with 
controls were analyzed to explain the absence of observed 
apoptosis in this particular normal cell line in contrast to 
the observed apoptosis seen in the previous control cell 
WI-38 when NSP 5a3a was over-expressed [7]. TRADD 
levels showed a significant increase in transfected cells 
compared to controls while in controls the TRADD levels 
were barely if at all detectable. TRAF2 levels showed a 
slight decrease in the 130 kDa band in transfected cells 
compared to controls. Bands detected at the 112 kDa and 
55 kDa range were comparable between transfected and 
controls. A slight increase in a 45 kDa band was detected 
in  the  transfected  compared  to  controls.  P73  levels 
showed a moderate to significant decrease in a 100 kDa 
band and a slight to moderate decrease in the 55 kDa in 
transfected cells compared to the controls. DAXX levels 
were detected at seemingly low levels around 72-75 kDa 
in controls though showed a decrease in the transfected 
cells being undetectable. B23 levels seemed moderately 
increased in transfected cells compared to the controls. 
There was no evidence of a lower molecular weight band 
for  NSP  5a3a  in  the  transfected  cells  (Fig.  9). Again, 
cleaved caspases 7, 8, 9, and 1 were tested and not detected 
for both transfected and controls (data not shown).
Molecular analysis of Co-immunoprecipitations 
in non-treated and NSP 5a3a over-expressing 
HN30 cells
Western  blot  analysis  of  non-treated  HN30  cells 
revealed an interaction between NSP 5a3a and DAXX/
TRAF2 as well as an interaction between NSP 5a3a and 
DAXX/TRAF2  in  apoptotic  cells  over-expressing  NSP 
5a3a in which we detected a 95 kDa band for DAXX and 
a 45 kDa band for TRAF2 (Fig. 10). Intensity of the bands 
for NSP 5a3a, DAXX, and TRAF2 seem slightly more 
intense in the transfected cells over-expressing NSP 5a3a 
compared to the non-treated cells though in the case of 
the NSP 5a3a, which still exhibits the doublet as in the 
Western blots of the total lysates of HN30 (Fig. 8), the 
lower molecular weight band seems less intense in the 
treated cells.
DISCUSSION
Programmed cell death, also known as apoptosis, 
is  an  active  daily  process  within  tissues  and  organs, 
necessary to ensure the proper functioning of the entire 
organism being critical for the regulation of development 
during growth and eventual homeostasis of tissues later 
in life. This finely tuned balance between cell death and 
proliferation  results  from  the  role  of  apoptosis  in  our 
normal physiological cellular turn-over and maintenance 
of  organ  functionality. When  this  process  of  apoptosis 
is  unbalanced  or  unregulated,  serious  pathological 
conditions can arise. Whole tissue and organ death have 
been associated with cardiovascular events such as heart 
attacks and strokes, while slower cellular death as been 
associated  with  particular  neurodegenerative  diseases 
such as dementia and Parkinsons [79-80].
Cancer cells seem to have escaped a limited lifespan, 
evading  natural  cell  turn  over  and  self-destruction  by 
silencing various endogenous executors and stimulators 
of apoptosis. It seems a fair assessment that the majority 
of modern day illnesses are associated with dysregulation 
of  the  apoptosis,  either  being  over-activated  or  under-
activated depending on the pathology [79-80]. The cancer 
cells  usually  suppress  apoptosis  by  three  fundamental 
mechanisms:  prevention  of  pro-caspase  activation; 
neutralization  of  activated  caspases;  and  silencing  of 
caspase  and  caspase-like  expression  at  the  gene  level. 
Many forms of cancer including leukemia, exhibit over-
expression  of  IAPs  (inhibitors  of  apoptosis)  such  as 
c-FLIP  and  CARD,  which  can  both  directly  interact 
with endogenous caspases and regulate their activation 
in  a  negative  manner,  thereby  impairing  the  necessary 
proteolytic cascade essential for apoptosis. Thus, apoptotic 
extrinsic  pathways  involving  TNFR/TRAIL-R  as  well 
as intrinsic pathways involving cytochrome c and AIF, 
through caspase dependent and independent mechanisms 
respectively via the mitochondria can all be abrogated by 
cancer cells in addition to their ability to alter expression 
levels and function of anti-apoptotic proteins such as Bcl-
2 family members [41, 79-81].
The  recent  investigative  effort  in  the  past  decade 
and  half  in  molecular  mechanisms  and  modulators  of 
apoptosis has generated a greater understanding of this 
complex  biological  process  and  its  association  with 
disease in the human body which as a result has pushed 
for the on-going development of novel strategies targeting 
various key components of the apoptotic process either 
in a pro-apoptotic or anti-apoptotic manner. Present on-
going apoptotic therapies targeting death receptors have 
included TRAIL through use of TRAIL-R1/R2 monoclonal 
antibodies  as  well  as  soluble Apo2L/TRAIL,  in  which 
most of these therapies have progressed to Phase 1 with 
exception of the Apo2L/TRAIL. Other apoptotic strategies 
so far have included targeting caspases such as caspase 1, 
3, 6, and 9 through activators of the caspase or inhibitor 
of the caspase’s inhibitor, as well targeting IAPs/SMAC 
by use of non-peptide small molecules or antisense oligos 
most of which have remained pre-clinical. There has been 
also development of small molecule inhibitors as well as Oncotarget 2011; 2:  1055 - 1074 1064 www.impactjournals.com/oncotarget
use of natural and synthetic compounds in targeting Bcl-
2 anti-apoptotic members which have remained mostly 
preclinical  with  the  exception  of  a  particular  antisense 
oligo in Phase 3 for treatment of leukemia, melanoma, 
multiple myelomas, and non-small lung cancer [80-81]. 
There  has  been  development  of  p53  targeted 
adenoviral therapies to re-introduce wild type p53 which 
have  reached  phase  3  in  treatment  of  Head  and  Neck 
cancer including other solid tumors as well as a phase 2/3 
combination therapy of advanced squamous cell cancer 
again  using  genetically  engineered  adenovirus  ONYX-
15 [80]. Though, despite the primary advantages of this 
system  being  high  level  of  transduction,  high  level  of 
gene expression, and being able to infect a broad spectrum 
of  cell  types  there  are  setbacks  and  issues  still  being 
addressed and being investigated regarding the issues of 
developing more cell/tissue specific vectors with minimal 
host  immune/inflammatory  responses  and  cytotoxicity 
as well as the preventing the generation of a replication 
competent virus, there still is need to consider and develop 
further  alternative  therapeutic  approaches  via  non-viral 
methods [82].
This subsequent study has revealed an interesting 
and  novel  mechanism  by  which  this  unique  structural 
protein NSP 5a3a induces apoptosis in HN30 cells lines, 
by seemingly stimulating extrinsic pathways of apoptosis 
internally, through two signaling events, one most likely 
involving p73/DAXX and the other involving TRAF2/
TRADD.
HN30  cells  over-expressing  NSP  5a3a  showed 
clearly  cellular  stress  from  apoptosis  (Fig.  1)  further 
more evident in the immunostaining of these cells (Fig. 
3-6) and as in our previous study, a significant decrease 
in a higher molecular weight p73 isoform at 140 kDa [7] 
was  detected  while  there  was  also  significant  decrease 
in a 45 kDa isoform along with a 55 kDa isoform to a 
lesser extent. Additionally, a 72 kDa isoform was also 
detected  though  seemed  comparable  in  levels  between 
controls and treated cells over-expressing NSP 5a3a (Fig. 
8).  Since  the  N-terminal  truncated  p73  isoforms  such 
as delta Np73, ex2p73, and ex2/3p73, have been found 
to be highly expressed in many cancers and known to 
possess  anti-apoptotic  activities  [83],  it’s  reasonable 
that in fact the isoforms of lower molecular weight we 
see  being  down-regulated  or  perhaps  degraded  are  in 
fact  anti-apoptotic  which  would  make  sense  given  the 
cellular response we observe when over-expressing NSP 
5a3a. The fact we used two anti-p73 antibodies (Santa 
Cruz  H-79)  and  (Santa  Cruz  S-20)  in  this  study,  we 
would expect a greater degree of detection and perhaps 
specificity of other isoforms not previously detected by 
the  (Santa  Cruz  H-79)  antibody  alone.  Typically,  the 
TAp73 isoforms such as: alpha, beta, gamma, and delta 
are linked to cell cycle arrest and apoptosis though which 
cell fate is determined depends on the cell type and also 
activating p53 target genes are activated and in which 
cell type [84]. Usually, apoptosis is evident by an up-
regulation of a TAp73 isoform as seen with TAp73 alpha 
and Tap73 beta [84]. Previously, it was suggested that the 
140 kDa along with the 72 kDa isoforms may be a result 
of some post-translational modification of a p73 isoform, 
since higher molecular weight isoforms of p73 have been 
identified around 75, 90 and 140 kDa in specific regions 
of  adult  human  brain  [85].  Since  it  has  been  shown 
that p73 can be ubiquitinated, in particular TAp73a and 
deltaNp73 isoforms can be ubiquitinated by Itch, which 
results in proteasomal-dependent degradation of these p73 
isoforms [86-87], it is plausible that the higher molecular 
weight of 140 kDa we observe may be the apoptotic form 
of  p73,  possibly  being  p73a  that  is  polyubiquitinated 
in  the  controls  while  in  the  cells  over-expressing  NSP 
5a3a,  there  is  a  decrease  in  its  polyubiquitinated  form 
resulting in more of the apoptotic isoform being present 
and stable to promote its activity. While MCF-12a cells 
over-expressing NSP 5a3a did not exhibit cellular stress 
being  apoptotic  in  appearance  as  evident  in  (Fig.  2) 
and the immunostaining (Fig. 3-6), the MCF-12a cells 
showed a 55 kDa isoform being down-regulated in cells 
over-expressing  NSP  5a3a  (Fig.  9)  though  we  cannot 
be certain if in fact this isoform is the same as the one 
observed in the HN30 cells, but is plausible since both 
apoptotic and anti-apoptotic functions have been assigned 
to these deltaNp73 isoforms [83,88] and interestingly, we 
observed a 100 kDa isoform being down-regulated in the 
MCF-12a cells over-expressing NSP 5a3a (Fig. 9), which 
again may be a post-translational modification such as 
ubiquitination of an anti-apoptotic form of p73 though 
in all cases, until more specific antibodies for such post-
translational modifications are tested, we cannot be sure 
of the exact nature of the type of covalent modification to 
these isoforms. The same plausibility would hold also in 
the case of sumoylation of p73, since it has been reported 
that for example SUMO-1 does covalently modify both 
full  length  TA  p73a  and  deltaNp73a  isoforms.  While 
usually sumoylation has been associated with different 
cellular  processes  such  as  transcriptional  regulation, 
subcellular transport regulation, influence protein stability 
and protein function in both cell cycle and apoptosis, in 
the case of p73a, its sumoylation has been associated with 
alteration in its subcellular localization and subsequent 
degradation [89-90]. 
In our previous study, we had found by use of a motif 
finder at http://motif.genome.jp/ a potential interaction site 
in NSP 5a3a with DAXX at at amino acid site: 276-330 
and thus wanted to confirm if such an interaction existed 
between the two proteins also given that fact that DAXX was 
known to be involved in the death doman receptor signaling 
pathway  involving  Fas  [91].  Co-immunoprecipitations 
of  HN30  non-treated  and  treated  cells  over-expressing 
NSP 5a3a revealed an interaction between NSP 5a3a and 
DAXX  while  seemingly  more  intense  in  treated  cells 
with a band at approximately 95 kDa (Fig. 10). DAXX Oncotarget 2011; 2:  1055 - 1074 1065 www.impactjournals.com/oncotarget
has been reported to act as a transcriptional repressor of 
many DNA-binding proteins [92-93], while it has been 
linked to both apoptotic and anti-apoptotic roles [91, 94] 
where silencing of DAXX sensitized cells to both Fas and 
stress-induced apoptosis [95]. In regards to its apoptotic 
role,  DAXX  has  been  associated  with  FAS  signaling, 
linking that signaling to the JNK pathway through ASK1 
activation.  Normally,  DAXX  is  predominantly  nuclear 
acting as a transcriptional repressor in the nucleus though 
under apoptotic conditions in which it mediates its effect 
through ASK1, it shuttles to the cytoplasm thus promoting 
caspase-independent  apoptosis  is  promoted  [96-99]. 
Interestingly, DAXX has been reported to interact with 
P73 acting as a transcriptional co-repressor of p53 and its 
members, by which this regulation is modulated by PML 
(promyelocytic  leukemia  protein)  occurring  in  nuclear 
PODs (PML oncogenic domains) [100]. HN30 cells over-
expressing  NSP  5a3a  showed  a  significant  increase  in 
DAXX with observation of a band between 72-75 kDa and 
a band between 120-130 kDa while being undetectable in 
controls (Fig. 8 ), and in fact similar distinct migratory 
DAXX forms have been reported in which a 70kDa form 
was known to be non-phosphorylated and known to have 
transcriptional co-repressor activity as also a 97 kDa and 
120 kDa bands have been identified relating to DAXX 
while the 120 kDa was revealed to be a result in part of a 
post-translational modification involving phosphorylation 
[101]. It is likely the 95 kDa may also be in part to a post-
translational modification in the conditions we observed. 
A similar band of 72-75 kDa was observed in controls 
of  the  MCF-12a  though  fairly  weak  and  being  nearly 
undetectable  in  MCF-12a  cells  over-expressing  NSP 
5a3a (Fig. 9). While we also detected a much lower band 
around 55 kDa in the HN30 treated cells we cannot be 
certain if this represents a non-specific band or perhaps 
some fragment of DAXX. Immunostaining of HN30 cells 
over-expressing NSP 5a3a showed a seemingly increased 
distribution of p73 from the nucleus into the cytoplasm, 
though not as quite as diffuse into the cytoplasm as the 
MCF-12a cells over-expressing NSP 5a3a (Fig. 4). Since 
the antibody used for the immunostaining for p73 was 
the rabbit polyclonal p73 (Santa Cruz H-79) and even 
though according the manufacturer the antibody should 
be  able  to  recognize  not  only  the  apoptotic  TAp73 
isoforms  (α,β,γ,δ,ε,η,ζ)  [83]  if  expressed  but  also  the 
anti-apoptotic forms ex2p73 (α,β,γ,δ,ε,η,ζ) and ex2/3p73 
(α,β,γ,δ,ε,η,ζ) [83], we were unable in our previous study 
to detect any bands that corresponded to those isoforms. 
Even though it is possible that this particular antibody 
may behave differently given the application it is used for 
thus allowing for different specificity and sensitivity, we 
cannot be sure if what we see by the immunostaining is 
solely the higher molecular weight isoform of 140 kDa 
in the case of the HN30 cells over-expressing NSP 5a3a. 
It’s been reported that TAp73  can localize in both the 
cytoplasm and nucleus while the deltaNp73 forms tend to 
localize mostly in the nucleus as seen in-vivo in breast and 
non-small lung cancer [102-103]. TAp73 and deltaNp73 
have  been  seen  mostly  in  nuclear  compartments  in-
vitro though there has been variation in its localization 
with  limited  cytoplasmic  localization  being  mostly 
nuclear  to  even  being  exclusively  cytoplasmic  as  seen 
in medullobastoma cell lines [104]. It is possible that we 
are observing an increased translocation of p73 from the 
nucleus to the cytoplasm due to an increase ubiquitination 
of the a particular p73 isoform/s, since it’s been shown that 
p73 is ubiquitinated in the nucleus, this process regulated 
by  PML  and  thus  then  shuttles  to  the  cytoplasm  for 
proteasomal degradation though cannot exclude should 
this particular p73 isoform/s may be instead sumoylated 
which can lead to proteasomal degradation as well [86, 
105] as also transcriptional repression involving DAXX in 
PODs [100]. Then again, p73 has been known to interact 
with DAXX and it has been suggested that p53/p73 may 
potentiate DAXX’s pro-apoptotic function when p53/p73 
associate with DAXX in the PODs of the nucleus [106]. 
Since  we  do  not  know  the  behavior  of  DAXX  during 
over-expression of NSP 5a3a nor its interaction with p73 
if still occurring in PODs regions of the nucleus or in 
other compartments, further study in needed to elucidate 
this likely signaling interaction involving p73 and DAXX. 
Thus, it is possible that NSP 5a3a may be assisting DAXX 
to regulate particular p73 isoforms perhaps in a negative 
manner in the PODs while enhancing its apoptotic activity 
with  other  p73  isoforms  depending  on  the  cell  type, 
cellular events in action and compartments in which they 
find themselves, yet also assisting DAXX to interact with 
other  apoptotic  proteins  most  likely  in  the ASK1-JNK 
pathway  in  parallel.  Given,  that  in  our  previous  study 
we had detected a Parp cleavage product of 89 kDa in 
HN30 cells over-expressing NSP 5a3a, which typically 
is associated with caspase activation in-vitro usually by 
caspase 3 as well as other caspases if caspase 3 is not 
available [107], we could not confirm any such activation 
and  having  been  already  documented  of  the  existence 
of Parp cleavage associated with caspase 3 independent 
activation [108-109] we further tested in this study if there 
was activation of other canonical caspases such as caspase 
9, 8, 7 and 1, in which we were not able to detect any 
cleaved products hence caspase activation which seems to 
point more in favor of a caspase independent mechanism, 
which has been associated with DAXX activation of the 
ASK1-JNK  pathway  [110].  Though  Parp  cleavage  is 
known as classical apoptotic hallmark [111] and it has 
been  documented  that  DAXX  ectopic  over-expression 
has  been  associated  with  caspase  dependent  activation 
by FAS and TRAIL induced apoptosis [112] one cannot 
exclude that depending on the cell system and apoptotic 
conditions being investigated that perhaps through NSP 
5a3a  over-expression,  DAXX  may  be  involved  in  a 
caspase independent activation of JNK pathway with Parp 
cleavage since Parp cleavage has been seen independent Oncotarget 2011; 2:  1055 - 1074 1066 www.impactjournals.com/oncotarget
of caspase activation [113-115]. Furthermore, given that 
an interaction between NSP 5a3a and a higher molecular 
weight  of  DAXX  at  95  kDa  was  confirmed  while 
modulation in a 72-75 kDa band as well as a 120-130 kDa 
was detected in the HN30 treated cells, this may indicate 
that NSP 5a3a preferentially interacts with a particular 
post-translational form of DAXX which may contribute 
to regulation and stability of the other DAXX un-modified 
and modified forms post-translationally. 
When we examined for other members involved in 
the ASK1-JNK pathway, we found by use of ELM motif 
finder at http://elm.eu.org/ potential sites on NSP 5a3a 
for interaction with TRAF2 at amino acid sites: 376-379 
(TTQE) and 455-458 (TLEE) as well as able to identify 
another  nine  potential  TRAF2  consensus  interaction 
sequences being the (SXXE) motif [116] in NSP 5a3. We 
thus were able to confirm an interaction between NSP 
5a3a  and  TRAF2  in  both  HN30  cells  over-expressing 
NSP 5a3a and non-treated cells, identifying in both cases 
a  band  approximately  45  kDa  (Fig.  10).  HN30  cells 
over-expressing NSP 5a3a showed a slight decrease in 
112 and 130 kDa isoforms compared to controls with a 
slight increase in a 190 kDa isoform and more moderate 
increase in a 55 kDa isoform compared to controls (Fig. 
8). We also observed a 45 kDa isoform which showed no 
apparent change in levels between treated and controls 
(Fig. 8). Similar bands were identified in MCF-12a cells 
though with a different pattern of expression in which a 
130 kDa isoform was slightly decreased in MCF-12a cells 
over-expressing NSP 5a3a while the 112 kDa and 55 kDa 
isoforms remained apparently the same between treated 
cells and controls (Fig. 9). The lower molecular weight 
45kDa  isoform  seemed  slightly  increased  in  MCF-12a 
cells over-expressing NSP 5a3a (Fig. 9). We can expect 
to see a broad range of isoforms since we used a rabbit 
polyclonal TRAF2 (Novus NB100-56173) antibody that 
has been documented to be able to detect a broad range 
of TRAF2  isoforms  again  depending  on  cell  type  and 
conditions. TRAF2 has been known well to be involved 
in the NF-KB pathway, both as positive regulator of the 
canonical pathway and as a negative regulator as well, in 
which depending on cell type and signaling intermediates 
and  adaptors  available  it  can  favor  or  not  cellular 
proliferation and survival [54, 117]. Though, it has been 
reported that TRAF2 can be involved in JNK activation 
leading to apoptosis by TNFa induction [118], by which 
TRAF2 can be polyubiquitinated at K63 resulting in its 
degradation and translocation to the cytoplasmic insoluble 
membrane fraction and cytoskeletal one as well [54, 119-
120]. Interestingly, we see modulation in protein levels of 
TRAF2 of both high and low molecular weight isoforms 
in the HN30 cells over-expressing NSP 5a3a, in which 
the  higher  molecular  weight  isoforms  may  be  in  fact 
post-translational modifications of TRAF2 lower weight 
isoforms resulting in polyubiquitination and given the fact 
we see an increased immunostaining for TRAF2 in the 
cytoplasm and association with likely apoptotic bodies 
as well (Fig. 5), it would seem plausible to support the 
idea that TRAF2 may be involved in mediating apoptotic 
signaling thru interaction of NSP 5a3a which could serve 
as  a  signaling  scaffold  for  TRAF2  isoforms.  It’s  been 
suggested that TRAF2 localization in the nucleus may be 
linked to transcriptional regulation while in the cytoplasm 
it may be linked to signal transduction [121]. In contrast, 
MCF-12a cells exhibited a more nuclear staining in the 
cells over-expressing NSP 5a3a compared to its controls 
though with lesser staining in the cytoplasm compared to 
the treated HN30 cells (Fig. 5). Even though both cell types 
expressed similar isoforms, it seems that in the MCF-12a 
the over-expression of NSP 5a3a did not induce the same 
intracellular stress response resulting in apoptosis, though 
in the case of the MCF-12a, the TRAF2 may be involved 
in activation or regulation of proteins involved in the NF-
KB pathway for example, leading to either 
prosurvival or cell cycle arrest. This we cannot be 
sure of in the case of the MCF-12a, since we would need 
further  study  of  the  cell  cycle  during  over-expression 
of NSP 5a3a and analysis of NF-KB pathway members 
as well. Even though, NF-KB signaling has been found 
to be involved in apoptosis depending on the nature of 
the  apoptotic  stimuli  [122-123]  it  usually  involves  the 
repression or down-regulation of target genes including 
TRAF2 [124], which ultimately makes more favorable the 
implication of TRAF2 in association with NSP 5a3a in 
the induction of apoptosis in HN30, whether the signal is 
being mediated through ASK1 leading to JNK activation 
or even through RIP which can lead to JNK activation and 
apoptosis also [125-126].
Another TNFR signaling protein known to interact 
with TRAF2 is TRADD particular to the TNFR1 pathway 
which can depending with which signaling and adaptor 
proteins it interacts with, it can either be involved in NF-
kB activation thru binding with TRAF2 or activation of 
apoptosis thru interaction with FADD [127-128]. While 
the  levels  of  TRADD  seemed  comparable  between 
controls  and  HN30  cells  over-expressing  NSP  5a3a 
(Fig. 8) there was an evident change in the distribution 
of  TRADD  as  indicated  by  the  immunostaining  (Fig. 
6) being more nuclear as well as more cytoplasmic in 
treated cells along with association with apoptotic bodies. 
In contrast, a significant increase in TRADD expression 
was  detected  in  MCF-12a  cells  over-expressing  NSP 
5a3a  while  being  undetectable  in  the  control  (Fig.  9) 
though  we  still  observed  its  expression  in  controls 
by  immunostaining  indicating  a  likely  difference  in 
sensitivity both in the behavior of the antibody used as 
well as the application. There seemed to me a more diffuse 
staining of TRADD into the cytoplasm of the MCF-12a 
treated  cells  compared  to  the  controls,  while  still  be 
mostly nuclear in both cases. While TRADD depending 
on its location in the cell can induce apoptosis by different 
mechanisms, either through a FADD/caspase 8 pathway Oncotarget 2011; 2:  1055 - 1074 1067 www.impactjournals.com/oncotarget
in the cytoplasm or through caspase 9 activation when in 
the nucleus [129], in both cases we exclude such pathways 
since  we  were  unable  to  detect  caspase  8/9  activation 
in the HN30 treated cells. The fact we see appreciable 
expression  levels  of  both  TRADD  and  TRAF2  in  the 
controls of the HN30 cells is of interest since it has been 
reported that the TNFR1-TRADD-TRAF2-RIP pathway 
is switched on in head and neck cell carcinoma leading 
to NF-kB constitutive activation and hence cell survival 
and proliferation [130]. Given this cellular behavior of 
the  head  and  neck  carcinoma  in  which  this  particular 
signaling pathway is already activated, it is plausible that 
NSP 5a3a may be altering this signaling pathway in favor 
of apoptosis through use of TRAF2 and TRADD. While 
in the MCF-12a cells, not showing the same cellular stress 
as in the HN30, NSP 5a3a-TRAF2 could be interacting 
with TRADD in promoting cell growth arrest or survival 
through the NF-kB pathway. Since we do not know the 
dynamics of interaction between TRADD and TRAF2 in 
the apoptotic conditions we observed, we cannot be sure if 
there is a novel interaction between TRADD and TRAF2 
mediated by NSP 5a3a that is involved in the promoting 
the apoptosis thru the ASK1/JNK pathway. Even though 
it has been shown that TRADD-TRAF2 interaction in the 
TNFR1 signaling pathway leads to NF-kB activation and 
cell survival, such that TRAF2 is not essential for TNFR1 
apoptotic  signaling  [117,  131]  we  cannot  exclude  a 
possible undefined interaction between NSP 5a3a/TRAF2 
with TRADD and other signaling and adaptor proteins that 
would allow the cells to die by apoptosis. Interestingly, 
though  there  no  evident  change  in  expression  in  the 
B23 levels in H30 cells over-expressing NSP 5a3a, as 
seen reported in our previous study [7], we did observe 
a moderate increase in B23 levels in the MCF-12a cells 
over-expressing  NSP  5a3a  which  may  be  contributing 
to the observed non-stressed and non-apoptotic state of 
these cells since B23 over-expression has been associated 
with cell cycle arrest and proliferation [132-133] though 
again we cannot be sure if the cells are in fact arrested 
in  particular  phase  of  the  cell  cycle  though  given  the 
expression of B23 along with TRADD and TRAF2 in 
the MCF-12a. Though, one cannot rule out that in this 
particular normal cell line, there may be a short circuit or 
interruption of induction of apoptosis and instead favoring 
either cell growth arrest or proliferation.
The HN30 cells over-expressing NSP 5a3a showed 
by immunostaining an increase in cytoplasmic localization 
compared  to  controls  while  also  being  associated  with 
likely apoptotic bodies. In contrast, the MCF-12a cells 
both  treated  and  controls  showed  still  mostly  nuclear 
staining without any significant change in localization of 
NSP 5a3a when over-expressed (Fig. 3). Similarly, there 
was also an association of TRADD and TRAF2 with or 
nearby apoptotic bodies in HN30 cells over-expressing 
NSP 5a3a (Fig. 5-6). While typically, apoptotic bodies and 
apoptotic blebs tend to be more associated with late stage 
apoptosis [134-135] being able to contain nuclear proteins, 
DNA, and RNA molecules [136] it would make sense that 
such proteins like: NSP 5a3a, TRADD and TRAF2, can 
exist and be included in such apoptotic bodies in such 
experimental conditions, which raises the question if these 
apoptotic bodies may be involved in extracellular induction 
of  apoptosis  with  neighboring  cells  since  it  has  been 
reported that apoptotic bodies can modulate intracellular 
communication [136-137]. Even though, mostly histone 
proteins 1-4 have been found inside apoptotic bodies as 
in  the  case  of  lymphoblasts  [138],  perhaps  depending 
on the type of apoptotic induction and cell type, TNFR 
signaling  proteins  could  remain  encapsulated  in  these 
apoptotic  bodies  as  in  our  case,  and  making  it  more 
intriguing is the fact that death receptor ligands, such as 
FasL and TRAIL have been found expressed on tumor 
microvesicles, albeit smaller than apoptotic bodies in size 
[139], in head and neck carcinoma from patients [140]. It 
opens possibilities if in the apoptotic scenario we present, 
that NSP 5a3a, TRAF2 and TRADD may be mediating 
apoptotic signals to other cells thru surface death receptor 
TNFR  via  apoptotic  bodies  or  blebs  that  are  formed. 
While, bleb formation has been also been found in early 
stages of apoptosis, being termed “marginal blebbing”, 
which leads to more advanced stages of actual formation 
and  separation  of  apoptotic  bodies  from  dying  cells, 
caspase activity was found associated with blebbing and 
apoptotic body formation, related to activation of at least 
either caspase 3 or 6 with also an increase in cytochrome c 
release from the mitochondria, this seen by TNFa induced 
apoptosis in Hela cells [141]. Though, again, we were not 
able to detect any caspase activity given the caspases we 
tested nor did we see any changes in cytochrome c levels 
as demonstrated in our previous study in HN30 treated 
cell [7].
We demonstrated in this subsequent study that NSP 
5a3a  seems  to  be  triggering  apoptosis  and  mediating 
its effects through 2 distinct axis points in the TNFR-1 
signaling pathway. One axis point involves p73 isoforms 
and DAXX while the other axis point involves TRAF2 
with possibly TRADD. How NSP 5a3a may modulate any 
possible cross-talk between these signaling axis points, 
how  these  apoptotic  adaptors  interact  with  each  other 
and with other signaling proteins, both in apoptotic and 
anti-apoptotic pathways depending on the cell type still 
warrants further investigation. It is known that scaffold 
proteins  enable  a  high  degree  of  specificity  between 
interacting proteins and substrates as well being catalysts 
in signaling pathways such as the MAPK/JNK pathways 
[142-143], thereby being able to function as molecular 
assembly platforms, allowing various domains of proteins 
to  interact  in  a  flexible  manner  [143].  Besides  being 
involved  in  regulating  cellular  communication  at  cell-
cell signaling junctions, coordinating assembly sequence 
interactions,  scaffold  proteins  also  have  been  found  to 
participate in intracellular signaling in regulation of kinase Oncotarget 2011; 2:  1055 - 1074 1068 www.impactjournals.com/oncotarget
cascade pathways, as well being themselves substrates for 
regulation in which a particular pathway may be switched 
on or off, and lastly being involved in regulatory feedback 
loops in a signaling pathway [143]. Interestingly, when we 
examined NSP 5a3a and compared its domain structure to 
recently identified scaffold proteins involved in MAPK/
JNK signaling, such as those proteins belonging to the JIP 
family, JIP1, JIP2, JIP3, and SPAG9 [144-145], we found 
an intriguing feature that NSP 5a3a shared with the JIP 
family proteins. Even though NSP 5a3a lacked particular 
domain features of the JIP family such as the JNK-binding 
domain, we did find potential MAPK/JNK docking sites 
known as the D-site in the NSP 5a3a amino acid sequence 
between amino acids: 361-515. The D-site is characterized 
by  the  following  consensus  sequence:  (R/K)3-5  (X)1-5 
(Φ-X-Φ) where there is a group of basic residues followed 
by a spacer region and then a hydrophobic submotif [146]. 
In light of the expanding multiple roles and functions of 
structural scaffolding proteins in normal and pathologic 
physiological states, it would be of great interest in future 
studies to better understand how NSP 5a3a may regulate 
and be regulated itself involving these recently discovered 
axis points along the ASK1/JNK pathway and its possible 
molecular  coordination  of  other  signaling  pathways 
that  may  cross-talk  and  converge  with  the ASK1/JNK 
pathway. Is it also of interest to investigate better how 
these axis points are coordinated between each other and 
how they may cross-talk, since it was recently reported 
that there is a cross-talk between p73 isoforms and c-JUN 
of the JNK pathway which can either lead to apoptosis or 
proliferation [147].
MATERIALS AND METHODS
Cell Lines and Tissue Culture
We used following cell lines in this study: HN30 
(Head and Neck carcinoma) and MCF-12a (Normal Breast 
Epithelial). All these cell lines were obtained from ATCC 
and cultured at conditions recommended by ATCC except 
for the HN30 cell line which was a kind gift from Dr. 
George Yoo of the Department of Otolaryngology, Head 
and Neck Surgery, Wayne State University and Karmanos 
Cancer Institute, Detroit, Michigan. 
DNA Transfection and Western Blot Analysis
Asynchronous  HN30  and  MCF-12a  cells  were 
seeded  in  6  well-plates  and  transfected  and  optimized 
with Fugene HD (Roche) according to the manufacturer’s 
protocol using 2 ug of plasmid DNA per well. Plasmids 
used  for  transfection  were  the  following:  pcDNA3.1/
CT-GFP  (invitrogen)  and  pcDNA  3.0  NSP  5a3a.  The 
NSP 5a3a cDNA had been cloned from a previous work 
[1]. The pcDNA3.1/CT-GFP vector was used to monitor 
transfection efficiency for all cell lines in the study.
  HN30  and  MCF-12a  cells  at  three  days  post-
transfection were harvested mechanically with a scraper, 
spun and washed twice with PBS 1x after which cells were 
prepped for western blot analysis. Cell pellets were lysed 
using a total lysis buffer (50mM Tris-Cl pH 7.4, 5mM 
EDTA, 250 mM NaCl, 50 mM NaF, .1% Triton X-100, .1 
mM Na3VO4, final volume with dH2O) for 15 minutes on 
ice then for 30 minutes on a rotator at 4 degrees. Lysates 
were spun down at 13,000 rpm for 15 minutes at 4 degrees 
after  which  supernatants  were  collected  and  protein 
concentration was determined by Bradford Assay. A total 
of 30 ug of total protein was loaded for each sample and 
separated on 7% SDS-PAGE or 15% gel depending on 
the molecular weight of the proteins to be separated then 
followed by transfer onto Whatman Protran Nitrocellulose 
Transfer Membrane for 1.5 hours at 70 volts at 4 degrees. 
Membranes  were  pre-blocked  overnight  at  4 
degrees in 5% milk buffer TTBS. Next day, membranes 
were cut and incubated with primary rabbit polyclonal 
NSP5a3a (Novus NB100-517A) at 1/500, primary rabbit 
polyclonal  p73  (  Santa  Cruz  H-79)  at  1/200,  primary 
goat polyclonal p73 (Santa Cruz S-20) at 1/200, primary 
mouse monoclonal alpha-tubulin (Invitrogen) at 1/5000, 
primary  rabbit  polyclonal  TRADD  (Cell  Signaling) 
1/1000, primary rabbit polyclonal TRAF2 (Novus NB100-
56173) at 1/1000, primary rabbit polyclonal DAXX (Cell 
Signaling  25C12)  at  1/1000,  primary  rabbit  polyclonal 
cleaved caspase 7 (Cell Signaling D198) at 1/x, primary 
rabbit polyclonal cleaved caspase 8 (Cell Signaling 18C8) 
at 1/x, rabbit primary polyclonal cleaved caspase 9 (Cell 
Signaling D3C5) at 1/x, primary rabbit polyclonal caspase 
1 (Cell Signaling) at 1/x or primary mouse monoclonal 
B23 (Sigma) at 1/500 in 5% milk buffer TTBS for 2 hours 
at RT. 
Membranes were then washed 4 times at 15 minute 
intervals in .1%Tween in PBS 1x then were incubated 
with secondary anti-rabbit HRP (Amersham Biosciences) 
at  1/5000,  secondary  anti-goat  HRP  (Amersham 
Biosciences)  at  1/5000  or  secondary  anti-mouse  HRP 
(Amersham Biosciences) at 1/5000 in 5% milk buffer for 
1 hour at RT. Membranes were then again washed 4 times 
at 15 minute intervals each and then exposed for 3 minutes 
to  ECL  Chemiluminescent  Detection  Reagent  (Perkin 
Elmer) to be developed on Kodak x-ray film. 
Co-immunoprecipitations and Western Blot 
Analysis
Asynchronous HN30 cells were plated in 60 mm 
Dishes so they would be approximately ~60% confluent 
next day for transfection. The day of transfection, HN30 
cells  were  transfected  with  recommended  amount  of 
pcDNA  3.0  NSP  5a3a  and  pcDNA  3.1/CT-GFP  using Oncotarget 2011; 2:  1055 - 1074 1069 www.impactjournals.com/oncotarget
Fugene  HD  (Roche)  as  indicated  by  the  manufacturer. 
Three  days  after  transfection,  HN30  cells  treated  with 
pcDNA  3.0  NSP  5a3a  and  pcDNA  3.1/CT-GFP  were 
harvested  along  with  non-treated  HN30  cells  using  a 
mechanical  scraper. The  cells  were  washed  twice  with 
PBS 1x after which Total lysis buffer was used to lyse 
cells.  While  cells  were  lysed,  100  ul  of  Protein  A/G 
sepharose beads (Pierce) were washed with 900 ul cold 
lysis buffer, spun down for ~30 seconds at 11,000 rpm, 
then washed again with 1 ml of cold lysis buffer, spun 
down and then were resuspended in 100 ul of cold lysis 
buffer and kept at 4 degrees until needed. Approximately, 
500-800  total  protein  for  both  treated  and  non-treated 
lysates were incubated with 25 ul of pre-washed protein 
A/G beads for 1 hour rotating at 4 degrees to pre-clear 
the lysates. After incubation with pre-washed beads, the 
lysates were spun down for 30 seconds at 11,000 rpm 
at 4 degrees, and then supernatants were transferred to 
prepped cold eppendorf tubes while the pre-cleared beads 
were saved at 4 degrees. The supernatants for both treated 
and  non-treated  were  then  split  into  equal  amounts  of 
total protein and were incubated with either 5 ug of rabbit 
polyclonal NSP 5a3a (Novus), rabbit polyclonal DAXX 
(Cell Signaling), or rabbit polyclonal TRAF2 (Novus) for 
1 hour rotating at 4 degrees. After supernatants incubated 
with their respective antibodies, approximately 25 ul of 
pre-washed protein A/G beads were added and allowed 
to incubate with the lysates plus antibodies rotating at 4 
degrees overnight. The next day, the supernatants were 
spun down for 30 seconds at 11,000 rpm after which the 
supernatants were removed and the beads were washed 
5 times with 500 ul of cold total lysis buffer. Then, 25 ul 
of Laemli 1x buffer with no beta-mercaptoethanol were 
added to the beads and not boiled after which the co-ips 
were loaded on a 7% SDS-PAGE gel and the membranes 
were immunoblotted accordingly with rabbit polyclonal 
NSP 5a3a (Novus) at 1/500, rabbit polyclonal DAXX (Cell 
Signaling) at 1/1000, or rabbit polyclonal TRAF2 (Novus) 
at 1/1000. Along with pre-cleared and pre-washed protein 
A/G beads, also primary rabbit IgGs was loaded on the 
gel as control.
Immunofluorescence Staining
Three  days  before  immuno-staining,  HN30  and 
MCF-12a cells were plated at a confluency of 150,000 
cells per well of a 6 well plate and grown onto sterile 
coverslips (22x22x1mm). The next day cells were either 
transfected with pcDNA 3.0 NSP 5a3a using Fugene HD 
(Roche) or left un-treated. Three days post-transfection, 
treated  and  non-treated  cells  were  washed  once  with 
serum free medium for 2-3 minutes at room temperature 
and  fixed  in  4%  paraformaldhyde  for  20  minutes  and 
permeabilized for 10 minutes at room temperature. Cells 
were pre-blocked for 1 hour at room temperature with 
8% BSA in PBS 1x, then cells were incubated with either 
with rabbit polyclonal NSP 5a3a (Novus NB100-517A) 
at 1/500, rabbit polyclonal TRADD (Cell Signaling) at 
1/1000, rabbit polyclonal TRAF2 (Novus NB100-56173) 
at 1/1000, or rabbit polyclonal p73 (Santa Cruz H-79) at 
1/200 dilution in 1% BSA overnight at 4ºC. Next day, 
the  primary  antibody  was  removed  and  then  after  3-5 
washes in PBS 1 x for 3-5 minutes each wash, cells were 
incubated  with  anti-rabbit  FITC  (Invitrogen)  at  1/700 
dilution in 1% BSA in PBS 1x and incubated for 1 hour 
at room temperature. Cover slips were mounted on glass 
slides with vector shield plus DAPI and edges of cover 
slips sealed with nail hardener. Images were acquired on 
an Olympus IX81 Confocal microscope with a 60x oil 
objective. Single plane images were taken with a sensicam 
qe  and  acquired  using  the  imaging  software  slidebook 
4.1.0. Images were taken in one plane at a .5 um thickness.
Light Microscopy
Asynchronous  HN30  and  MCF-12a  cells,  three 
days post-transfection were observed for morphological 
changes  using  Zeiss Axiovert  25  microscope  with  10x 
PH1 Zeiis objective.
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